Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini Sells 1,562 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,562 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $9.15, for a total transaction of $14,292.30. Following the completion of the sale, the chief accounting officer now directly owns 28,189 shares of the company’s stock, valued at approximately $257,929.35. This trade represents a 5.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vir Biotechnology Trading Up 0.7 %

Shares of Vir Biotechnology stock opened at $9.65 on Friday. The company has a 50-day simple moving average of $9.13 and a 200 day simple moving average of $8.48. Vir Biotechnology, Inc. has a 12-month low of $6.56 and a 12-month high of $14.45.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. JPMorgan Chase & Co. increased their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday, January 9th. HC Wainwright restated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, January 31st. Leerink Partners increased their price objective on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Finally, Barclays dropped their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.83.

Institutional Investors Weigh In On Vir Biotechnology

Hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its holdings in Vir Biotechnology by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,987 shares of the company’s stock worth $436,000 after acquiring an additional 3,605 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in Vir Biotechnology by 27.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 57,446 shares of the company’s stock worth $430,000 after acquiring an additional 12,511 shares during the last quarter. nVerses Capital LLC bought a new stake in Vir Biotechnology during the 3rd quarter worth about $56,000. Blue Trust Inc. grew its holdings in Vir Biotechnology by 143.5% during the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after acquiring an additional 2,351 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Vir Biotechnology by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 26,280 shares of the company’s stock valued at $197,000 after purchasing an additional 10,294 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).